Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 183

Sort by

Sort Order Select

Journal Articles

Ibromics: A Real-World Study of Clinical and Biological Parameters in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line with Single Agent Ibrutinib

Cecilia Muñoz-Calleja, José Ángel Hernández-Rivas, Francesc Bosch, Laura Palomo, Adrian Mosquera Orgueira, Angel Ramirez, Ruben Fernandez Alvarez, Ana C Oliveira, Paula Amat Martinez, Alicia Serrano, Aránzazu García-Grande, Ana Yeguas, Marta Crespo, Miguel Alcoceba, Blanca Ferrer Lores, José Antonio Garcia Vela, Luis Espinosa-Hevia, Celia Bolumburu, Miguel Villanueva Forero

Blood (2024) 144 (Supplement 1): 6769.

https://doi.org/10.1182/blood-2024-199097

Published: 2024

Journal Articles

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Daniel Medina, Laura Palomo, Víctor Navarro, Cristina García, Juan Camilo Nieto, Júlia Carabia, Carlota Pagès Geli, Pamela Acha, Gemma Pujadas, Carlos Palacio, Laura Gallur, Josep Castellvi, Pau Abrisqueta, Francesc Bosch, Marta Crespo

Blood (2024) 144 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2024-205108

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Blood (2024) 144 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2024-201373

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Gloria Hidalgo-Gomez, Bárbara Tazón-Vega, Carlos Palacio, Silvia Saumell, María Gabarrós-Subirà, Andres Jerez, Adoracion Blanco, Noemí Martínez-Morgado, Víctor Navarro Garces, Laura Murillo, Pablo Velasco, Thais Murciano, Cristina Díaz De Heredia, Francesc Bosch, Gemma Armengol, Margarita Ortega

Blood (2024) 144 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2024-209957

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Blood (2024) 144 (Supplement 1): 597.

https://doi.org/10.1182/blood-2024-207189

Published: 2024

Journal Articles

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Blood (2024) 144 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2024-207871

Published: 2024

Journal Articles

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Blood (2024) 144 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2024-211133

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

Marina Serra Carrera, Macarena Simón-Talero, Desiree Campoy, Gonzalo Artaza, Mercedes Perez Lafuente, Sergi Camarillas, Sofia Laura Muzio, Jonay Mendez, Maria Landwehr, Francesc Bosch, Pável E Olivera

Blood (2024) 144 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2024-209784

Published: 2024

Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2024) 144 (Supplement 1): 886.

https://doi.org/10.1182/blood-2024-198147

Published: 2024

Journal Articles

Evaluation of the Prognostic Impact of STAG2 in the Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Francisco Beas, Sandra Novoa Jáuregui, María Gabarrós-Subirà, María Eugenia Rivero, Clàudia Pellín Jou, Pamela Acha, Alba Puyuelo, Silvia Saumell, Ana María Garrido, Félix López Cadenas, Ana Pérez, Carlos Eduardo Chávez, Adoracion Blanco, Laura Gallur, Gloria Hidalgo-Gómez, Francesc Bosch, Maria Julia Montoro, David Valcarcel, Andres Jerez

Blood (2024) 144 (Supplement 1): 6742.

https://doi.org/10.1182/blood-2024-206758

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

T C, Eva Minga, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, David Allsup, Francesca Bacchiarri, Sotiria Besikli-Dimou, Sofia Chatzileontiadou, Rosa Collado, Zadie Davis, Maria Dimou, David Donaldson, Maria Efstathopoulou, Sara Galimberti, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Eleftheria Hatzimichael, Jose-Angel Hernandez-Rivas, Gloria Iacoboni, Iliana Konstantinou, Ioannis Kotsianidis, Jana Kotaskova, Andreas Epameinondas Koumpis, Zuzana Kubova, Jorge Labrador, Luca Laurenti, Juan Marquet, Stanislava Maslejova, Carlota Mayor-Bastida, Fatima Miras, Riccardo Moia, Almudena Navarro-Bailon, Jacopo Olivieri, Maria Papaioannou, Anna Puiggros, Gian Matteo Rigolin, Mattia Schipani, Tereza Shokralla, Martin Simkovic, Antigoni Tranidou, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Renata Walewska, Lucrecia Yanez San Segundo, Jana Zuchnicka, David Graham Oscier, Alessandro Gozzetti, Panayiotis Panayiotidis, Francesc Bosch, Paolo Sportoletti, Blanca Espinet, Gerassimos Pangalis, Maria Angelopoulou, Tomas Papajik, Roberta Murru, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Niki Stavrogianni, Livio Trentin, Lukas Smolej, Mark Caterwood, Martin Spacek, Sarka Pospisilova, Michael Doubek, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2024) 144 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2024-202046

Published: 2024

Journal Articles

Clonal Hematopoiesis in Relatives of Adults with Myeloid Neoplasms with Germline Predisposition

Sandra Novoa Jáuregui, Sara Torres-Esquius, Maria Gabarros Subira, Ana María Garrido, Clàudia Pellín Jou, Pamela Acha, Adriana Oñós, Silvia Saumell, Bárbara Tazón-Vega, Ana Perez Gonzalez, Laura Palomo, Adoracion Blanco, David Valcarcel, Francesc Bosch, Andres Jerez, Maria Julia Montoro

Blood (2024) 144 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2024-209611

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

NARROW

Ibromics: A Real-World Study of Clinical and Biological Parameters in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line with Single Agent Ibrutinib

Immune Crosstalk Profiling of Non-Hodgkin Lymphoma (NHL) Tumor Immune Microenvironment Identifies Two Clusters Based on T Cell Exhaustion, Correlating with Different Clinical Outcomes

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Evaluation of the Prognostic Impact of STAG2 in the Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Clonal Hematopoiesis in Relatives of Adults with Myeloid Neoplasms with Germline Predisposition

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only